Symbol | Exchange | Currency |
|---|
Investing.com - Inhibrx (NASDAQ: INBX) reported first quarter EPS of $-1.12, $0.26 worse than the analyst estimate of $-0.86. Revenue for the quarter came in at $17K versus the...
Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has...
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
| Average | 49.00 (+102.81% Upside) |
| High | 60.00 |
| Low | 35.00 |
| Price | 24.16 |
| No. of Analysts | 4 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Neutral | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | NASDAQ | |||
| 121.19 | 121.34 | 119.08 | +1.70 | +1.42% | 295.91K | NYSE | |||
| 35.83 | 37.51 | 35.81 | -1.41 | -3.79% | 2.78M | NYSE | |||
| 7.70 | 7.84 | 7.54 | +0.16 | +2.12% | 43.11M | NYSE | |||
| 20.00 | 20.30 | 19.65 | +0.27 | +1.37% | 13.00K | NYSE | |||
| 13.11 | 13.16 | 12.95 | +0.10 | +0.77% | 1.76M | NYSE | |||
| 10.57 | 10.60 | 10.56 | 0.00 | 0.00% | 0.00 | NYSE | |||
| 0.0113 | 0.0113 | 0.0113 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 12.26 | 12.97 | 12.13 | -0.71 | -5.47% | 7.45M | NASDAQ | |||
| 59.00 | 60.40 | 58.97 | -0.30 | -0.51% | 10.09M | NYSE | |||
| 0.637 | 0.665 | 0.625 | -0.013 | -2.00% | 6.46M | NASDAQ | |||
| 166.15 | 170.00 | 159.55 | +7.27 | +4.58% | 2.10M | NASDAQ | |||
| 6.51 | 6.58 | 6.46 | +0.04 | +0.62% | 2.45M | NYSE | |||
| 0.135 | 0.144 | 0.135 | -0.005 | -3.43% | 249.91K | NASDAQ | |||
| 39.89 | 40.50 | 39.63 | 0.00 | 0.00% | 0.00 | NYSE |